ClinicalTrials.gg

Program

INNA-051

Its studies are mostly in Influenza, Human · COVID-19, led by ENA Respiratory Pty.

Furthest: phase 2, since Oct 27, 20213 company-led studies, 1 open or runningNext primary completion: Mar 12, 2027 (phase 2)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
ENA Respiratory Pty31 open or runningphase 2since Oct 27, 2021Oct 27, 2021Mar 12, 2027phase 2 · NCT07222670

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Oct 27, 2021First study: phase 2 study in COVID-19First studyNCT05118763
  2. Jan 27, 2022Phase 2 study in Influenza ProphylaxisNCT05255822 · 123 enrolled · United Kingdom
  3. Oct 28, 2025Phase 2 study in Viral Respiratory InfectionNCT07222670 · 1,100 planned · United States

Ahead

  1. Mar 12, 2027Primary completion: phase 2 study in Viral Respiratory InfectionNCT07222670

TargetBeta

TLR2 →read by rule
“INNA-051, a TLR2/6 agonist, is being developed as an intranasal innate immune-boosting prophylactic approach for individuals at risk for symptoms and/or complications resulting from respiratory viral infections due to age, occupation, and/or co-morbidities.”study text, by rule · the study

Other programs on TLR2

ProgramCompanyFurthest phaseStudies
NM-101ruleneuramedy-co-ltdphase 12

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07222670Viral Respiratory Infection · United States2RecruitingMar 12, 20271,100
NCT05255822Influenza Prophylaxis · United Kingdom2CompletedAug 23, 2022123
NCT05118763COVID-192WithdrawnDec 31, 20220

How it is read

Names in the registry

  • “INNA-051”, 3 entries

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.